Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cb-839
1. Cb-839
2. 1439399-58-2
3. Telaglenastat [usan]
4. Cb839
5. Cb 839
6. 2-(pyridin-2-yl)-n-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide
7. U6cl98glp4
8. N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
9. 2-(pyridin-2-yl)-n-(5-{4-[6-({[3-(trifluoromethoxy)phenyl]acetyl}amino)pyridazin-3-yl]butyl}-1,3,4-thiadiazol-2-yl)acetamide
10. 2-pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-
11. 2-(pyridin-2-yl)-n-{5-[4-(6-{2-[3-(trifluoromethoxy)phenyl]acetamido}pyridazin-3-yl)butyl]-1,3,4-thiadiazol-2-yl}acetamide
12. 2-pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-
13. 63j
14. N-(6-(4-(5-(2-(pyridin-2-yl)acetamido)-1,3,4-thiadiazol-2-yl)butyl)pyridazin-3-yl)-2-(3-(trifluoromethoxy)phenyl)acetamide
15. N-[6-(4-{5-[2-(pyridin-2-yl)acetamido]-1,3,4-thiadiazol-2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
16. Cb-839(telaglenastat)
17. Unii-u6cl98glp4
18. Telaglenastat [inn]
19. Telaglenastat (usan/inn)
20. Telaglenastat [who-dd]
21. Gtpl9053
22. Cb-839 [who-dd]
23. Chembl3639788
24. Schembl14987180
25. Bdbm109086
26. Hms3741e19
27. Hms3873g13
28. Amy16835
29. Bcp28287
30. Ex-a1310
31. Mfcd28167826
32. Nsc783415
33. Nsc795998
34. Nsc798057
35. S7655
36. Who 10815
37. Akos025396175
38. Zinc169698697
39. Ccg-270102
40. Cs-3393
41. Db15232
42. Nsc-783415
43. Nsc-795998
44. Nsc-798057
45. Sb17221
46. Ncgc00356145-11
47. 2-?pyridineacetamide, N-?[5-?[4-?[6-?[[2-?[3-?(trifluoromethoxy)?phenyl]?acetyl]?amino]?-?3-?pyridaz
48. Ac-31603
49. As-75090
50. Cb839; Cb 839 Pound>>telaglenastat,
51. Da-34988
52. Hy-12248
53. Ft-0767818
54. A14396
55. D11738
56. A857288
57. Us8604016, 670
58. Q27075751
59. 2-?pyridineacetamide, N-?[5-?[4-?[6-?[[2-?[3-?(trifluoromethoxy)?phenyl]?acetyl]?amino]?-?3-?pyridazinyl]?butyl]?-?1,?3,?4-?thiadiazol-?2-?yl]?-
60. N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide
61. N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide;cb-839
Molecular Weight | 571.6 g/mol |
---|---|
Molecular Formula | C26H24F3N7O3S |
XLogP3 | 3.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 12 |
Exact Mass | 571.16134331 g/mol |
Monoisotopic Mass | 571.16134331 g/mol |
Topological Polar Surface Area | 160 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 812 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
17
PharmaCompass offers a list of Telaglenastat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Telaglenastat manufacturer or Telaglenastat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Telaglenastat manufacturer or Telaglenastat supplier.
PharmaCompass also assists you with knowing the Telaglenastat API Price utilized in the formulation of products. Telaglenastat API Price is not always fixed or binding as the Telaglenastat Price is obtained through a variety of data sources. The Telaglenastat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Telaglenastat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Telaglenastat, including repackagers and relabelers. The FDA regulates Telaglenastat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Telaglenastat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Telaglenastat supplier is an individual or a company that provides Telaglenastat active pharmaceutical ingredient (API) or Telaglenastat finished formulations upon request. The Telaglenastat suppliers may include Telaglenastat API manufacturers, exporters, distributors and traders.
Telaglenastat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Telaglenastat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Telaglenastat GMP manufacturer or Telaglenastat GMP API supplier for your needs.
A Telaglenastat CoA (Certificate of Analysis) is a formal document that attests to Telaglenastat's compliance with Telaglenastat specifications and serves as a tool for batch-level quality control.
Telaglenastat CoA mostly includes findings from lab analyses of a specific batch. For each Telaglenastat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Telaglenastat may be tested according to a variety of international standards, such as European Pharmacopoeia (Telaglenastat EP), Telaglenastat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Telaglenastat USP).